注射用益气复脉(冻干)治疗慢性心力衰竭的预算影响分析

Budget impact analysis of Yiqifumai injection( lyophilization) on heart failure patients

目的为药品报销目录的遴选决策、药品降价谈判及确立医保支付价格提供借鉴和参考。方法基于预算影响分析模型,查阅文献、统计年鉴、CFDA南方医药经研究所的重点城市公立医院中成药与化学药终端监测分析系统(简称HDM系统),以及天津天士力之骄药业有限公司提供的益气复脉2013~2016年销售额等数据,比较分析了目前市场上用于治疗慢性心力衰竭的主要中药注射剂的市场组成,并预测未来五年内(2017~2021年)益气复脉未纳入医保目录与益气复脉纳入医保目录两种情形下医保基金总支出。结果如果2017年益气复脉纳入国家医保目录,价格适度调整后,预计未来五年医保基金结余将逐年递增,累计结余约2亿元。结论预计注射用益气复脉(冻干)能够为医保节约开支,建议将注射用益气复脉(冻干)纳入医保目录。

Objective This study provides reference for the selection decision of health insurance catalog medicine, health insurance drug negotiation and the determination of health insurance payment price. Methods Based on the budget impact analysis model, the data of treatment of acute myocardial infarction were analyzed by reviewing the literattire, health statistics yearbook, CFDA Southern Medical Research Institute HDM system, and sales data provided by Tianjin Tasly Pride Pharmaceutical Co. Ltd. The market share of the main Chinese medicine injections for the treatment of chronic heart failure were studied to predict the total expenditure of health insurance fund if Yiqifumai is included in the health insurance catalog or if it is not included in the next five years. Results If Yiqifumai injection （lyophilization） is included into the 2017 national health insurance catalog and its price can be moderately adjusted, the health care fund balance will increase year by year within the next five years, and the cumulative balance of health insurance fund will reach 200 million yuan. Conclusion It is expected that Yiqifumai injection （lyophilization） can save budget for health insurance expenditure, and we recommend that it should be included into health insurance catalog.